Cationic Liposome RNA Binding and Stabilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current RNA delivery systems face challenges such as toxicity of viral vectors, ineffectiveness of non-viral carriers, and the need for efficient delivery and protection of nucleic acids to target sites, particularly in gene therapy and anticancer treatments.
Innovation Solution
Development of cationic liposomes composed of specific lipid ratios, including neutral, cationic, and polyethylene glycol-modified lipids, loaded with RNA and emetine, which provides stable binding and targeting capabilities, especially with the addition of a folic acid targeting agent for enhanced delivery to cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If viral vectors are used to deliver RNA, then delivery effectiveness is improved, but toxicity increases
Solution Approach 1:
The patent uses cationic liposomes as intermediary carriers to deliver RNA therapeutics. These liposomes consist of cationic lipids that bind to negatively charged RNA, forming stable complexes that protect the RNA from degradation and enable targeted delivery to cells, thereby achieving effective delivery without the toxicity associated with viral vectors
Solution Approach 2:
The patent optimizes the composition parameters of the liposomal carrier system, including the ratio of cationic to neutral lipids, the molecular weight and charge density of the cationic lipids, and the size of the liposomal particles. These parameter optimizations enable the system to achieve both high delivery effectiveness and low toxicity by tuning the physical and chemical properties of the carrier
2Object-affected harmful factors
If non-viral carriers are used to deliver RNA, then toxicity is reduced, but delivery effectiveness decreases
Solution Approach 1:
The patent employs composite liposomal structures combining cationic lipids, neutral lipids, and cholesterol in specific ratios. This composite material approach creates a carrier system that maintains low toxicity while achieving high delivery effectiveness through the synergistic properties of different lipid components that enhance stability, cellular uptake, and RNA protection
Solution Approach 2:
The liposomal carrier uses a flexible phospholipid bilayer shell that can adapt to cellular membranes and facilitate endosomal escape. The thin film structure allows for efficient RNA encapsulation while maintaining carrier flexibility and biocompatibility, thereby achieving effective delivery without viral toxicity
3Device complexity
If RNA is delivered without protection, then delivery simplicity is improved, but RNA stability decreases due to nuclease degradation
Solution Approach 1:
The patent implements a nested structure where RNA is encapsulated within the liposomal carrier. The negatively charged RNA is bound and protected by the positively charged cationic lipids inside the liposome, forming a protected core that shields the RNA from external nucleases while maintaining a relatively simple overall delivery system
4Duration of action of stationary object
If liposome size is reduced to avoid renal elimination, then circulation time is improved, but cellular uptake efficiency decreases
Solution Approach 1:
The patent optimizes the size parameter of the liposomal carrier to a specific range (typically 50-200 nm) that balances renal filtration avoidance with cellular uptake efficiency. This parameter optimization, along with adjusting surface charge and lipid composition, enables the liposomes to circulate effectively while maintaining high cellular internalization rates
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The liposomes achieve high encapsulation efficiency of emetine, stable RNA binding, and selective targeting of cancer cells, demonstrating improved delivery and therapeutic potential with minimal side effects.
Implementation Method 1
The first nucleic acid sequences used in gene therapy were in the form of plasmid DNA, while the recently introduced RNA-based drugs... characterised by much higher effectiveness
Implementation Method 2
NP systems, on the other hand, are large enough to avoid renal elimination and can provide greater protection for circulating nucleic acids
Implementation Method 3
Over the last few years, there has been tremendous progress in the development of non-viral systems for the in vivo targeted delivery of genes to various organs
Data Source
AI summary
The present invention relates to a cationic liposome that binds and stabilises RNA, its use and a method for loading the liposome with emetine. The liposome consists of neutral lipids in the amount of 12.4 to 49% by weight, cationic lipids in the amount of 16.2 to 55% by weight, polyethylene glycol-modified lipids in the amount of 12.9 to 15.1% by weight and cholesterol in an amount from 15.4 to 18.1% by weight, and is characterised by a size from 80 nm to 190 nm, a polydispersity index from 0.06 to 0.23, and a zeta potential from +19 mV to +55 mV, wherein it is loaded with RNA.